New York City, NY, November 10, 2017/24 Market Reports: Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Scope of the Report:
This report focuses on the Drugs for Herpes Labialis (Oral Herpes) in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- GSK
- Novartis
- Teva
- Mylan
- Cadila
- Apotex
- Daewoong Pharmaceutical
- Livzon
- Luoxin
- Med shine
- Bayer (Campho Phenique)
- Blistex
- Kelun Group
- Hikma
- Haiwang
- Carmex
- Cipher
Market Segment by Regions, regional analysis covers
- North America (USA, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Columbia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Aciclovir
- Valacyclovir
- Famciclovir
- Docosanol
- Other
Market Segment by Applications, can be divided into
- External Use
- Oral
- Injection
Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/global-drugs-for-herpes-labialis-oral-herpes-market-by-manufacturers-countries-type-and-application-forecast-to-2022